Ocrevus (ocrelizumab) - Haʻawina Pono

ʻOcrevus (ocrelizumab) he lāʻau olaola i hoʻohana ʻia no ka mālama ʻana i ka maʻi sclerosis (MS) a me ka rheumatoid arthritis (RA). Ua ʻae ʻia ka lāʻau lapaʻau e ka FDA ma 2017 no ka mālama ʻana iā MS a ma 2021 no ka mālama ʻana iā RA.

Hoʻokumu ʻia ka hana a Ocrevus ma ke kāohi ʻana i ka protein CD20, aia ma ka ʻili o kekahi mau cell o ka ʻōnaehana pale, me nā cell e hana nui i ka hoʻomohala ʻana o MS a me RA. ʻO ka pale ʻana i ka protein CD20 hiki ke hōʻemi i ka hana o ka ʻōnaehana pale a hoʻemi i ka mumū e alakaʻi ai i ka pōʻino o ke kino.

Ua mālama ʻia nā haʻawina e pili ana i ka pono o Ocrevus i ka mālama ʻana iā MS a me RA no kekahi mau makahiki. ʻO kekahi o nā haʻawina mua, i paʻi ʻia ma The Lancet ma 2017, ua kapa ʻia ʻo "Efficacy and safety of Ocrevus in primary progressive multiple sclerosis." Ua mālama ʻia ke aʻo ʻana ma luna o 700 mau maʻi i loaʻa iā Ocrevus a i ʻole placebo no 96 mau pule. Ua hōʻike nā hopena ua hoʻemi nui ʻo Ocrevus i ka holomua o MS i hoʻohālikelike ʻia me kahi placebo.

ʻO kekahi noiʻi ʻē aʻe i paʻi ʻia ma The New England Journal of Medicine ma 2017 i noiʻi i ka pono o Ocrevus i ka hoʻihoʻi hou ʻana i ka maʻi sclerosis (RRMS). Ua mālama ʻia ka haʻawina ma mua o 1300 mau maʻi i loaʻa iā Ocrevus a i ʻole kekahi lāʻau lapaʻau no ka mālama ʻana i ka RRMS. Ua hōʻike ʻia nā hopena ua hōʻemi nui ʻo Ocrevus i ka nui o nā relapses i nā maʻi i hoʻohālikelike ʻia i ka lāʻau lapaʻau ʻē aʻe.

Ua mālama ʻia nā haʻawina e pili ana i ka pono o Ocrevus ma RA. ʻO kekahi o lākou, i paʻi ʻia ma The Lancet ma 2019, ua nānā i ka maikaʻi o Ocrevus i ka seropositive RA, ʻo ia kekahi o nā mea koʻikoʻi loa.